Skip to main content

PIM Kinases in Multiple Myeloma.

Publication ,  Journal Article
Wu, J; Chu, E; Kang, Y
Published in: Cancers (Basel)
August 26, 2021

Multiple myeloma (MM) remains an incurable disease and novel therapeutic agents/approaches are urgently needed. The PIM (Proviral insertion in murine malignancies) serine/threonine kinases have 3 isoforms: PIM1, PIM2, and PIM3. PIM kinases are engaged with an expansive scope of biological activities including cell growth, apoptosis, drug resistance, and immune response. An assortment of molecules and pathways that are critical to myeloma tumorigenesis has been recognized as the downstream targets of PIM kinases. The inhibition of PIM kinases has become an emerging scientific interest for the treatment of multiple myeloma and several PIM kinase inhibitors, such as SGI-1776, AZD1208, and PIM447 (formerly LGH447), have been developed and are under different phases of clinical trials. Current research has been focused on the development of a new generation of potent PIM kinase inhibitors with appropriate pharmacological profiles reasonable for human malignancy treatment. Combination therapy of PIM kinase inhibitors with chemotherapeutic appears to create an additive cytotoxic impact in cancer cells. Notwithstanding, the mechanisms by which PIM kinases modulate the immune microenvironment and synergize with the immunomodulatory agents such as lenalidomide have not been deliberately depicted. This review provides a comprehensive overview of the PIM kinase pathways and the current research status of the development of PIM kinase inhibitors for the treatment of MM. Additionally, the combinatorial effects of the PIM kinase inhibitors with other targeted agents and the promising strategies to exploit PIM as a therapeutic target in malignancy are highlighted.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancers (Basel)

DOI

ISSN

2072-6694

Publication Date

August 26, 2021

Volume

13

Issue

17

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wu, J., Chu, E., & Kang, Y. (2021). PIM Kinases in Multiple Myeloma. Cancers (Basel), 13(17). https://doi.org/10.3390/cancers13174304
Wu, Jian, Emily Chu, and Yubin Kang. “PIM Kinases in Multiple Myeloma.Cancers (Basel) 13, no. 17 (August 26, 2021). https://doi.org/10.3390/cancers13174304.
Wu J, Chu E, Kang Y. PIM Kinases in Multiple Myeloma. Cancers (Basel). 2021 Aug 26;13(17).
Wu, Jian, et al. “PIM Kinases in Multiple Myeloma.Cancers (Basel), vol. 13, no. 17, Aug. 2021. Pubmed, doi:10.3390/cancers13174304.
Wu J, Chu E, Kang Y. PIM Kinases in Multiple Myeloma. Cancers (Basel). 2021 Aug 26;13(17).

Published In

Cancers (Basel)

DOI

ISSN

2072-6694

Publication Date

August 26, 2021

Volume

13

Issue

17

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis